Nadroparin calcium

When ATH:
B01AB06

Characteristic.

1 U nadroparina calcium corresponds to 0,41 ME anti-Ha.

Pharmacological action.
Antykoahulyantnoe.

Application.

Deep vein thrombosis, thromboembolism pulmonary embolism, acute coronary syndrome, Prevention of thrombosis in patients with high risk: and) orthopedic, oncology and general surgery, to) hemodialysis and hemofiltration in patients with chronic renal failure.

Contraindications.

Hypersensitivity, bleeding (incl. history, except consumption coagulopathy), encephalorrhagia (except systemic embolism), acute bacterial endocarditis, pericarditis, aggravation of gastric ulcer and duodenal ulcer, CNS trauma, condition after spinal puncture, radiotherapy, thrombocytopenia assay with positive aggregation in vitro in the presence of the drug, use of intrauterine contraceptive mechanical means, postpartum.

Restrictions apply.

Arterial hypertension, postural hypotension, swoon, chorioretinopathy, vasculitis, severe renal and hepatic failure, pronounced diabetes.

Pregnancy and breast-feeding.

Not recommended.

Side effects.

Thrombocytopenia, bleeding (GI, urinary tract), hemorrhage (in the ovaries, yellow body, adrenals with the development of acute adrenal insufficiency), allergic reactions (fever, rash, bronchial asthma, nausea, vomiting), hematoma and necrosis at the injection site.

Cooperation.

Proximity effect anticoagulants, antiagregantov, NSAIDs, dextran, tetracyclines. Cardiac glycosides, ethacrynic acid, antihistamines weaken anticoagulant activity. Tetracyclines enhance the effect of nadroparin calcium. Nicotinic acid modifies the effect of nadroparin calcium.

Overdose.

Symptoms: bleeding.

Treatment: in/in the introduction antagonist-protamine sulfate (0,6 ml each 0,1 ml nadroparina calcium), simptomaticheskaya therapy.

Dosing and Administration.

Injected into the subcutaneous tissue of the abdomen (the needle is perpendicular to the skinfold).

With the purpose of treatment: 2 twice a day for 10 days, dose 225 U / kg (100 IU / kg), corresponding: 45-55 kg-0.4-0.5 ml; 55-70 kg-0.5-0.6 ml; 70-80 kg-0.6-0.7 ml; 80-100 kg- 0,8 ml; more 100 kg - 0,9 ml.

For the prevention of thromboembolic complications in surgical practice: n / a 0,3 ml for 2-4 hours before the start of the operation and 0,3 ml 1 once a day in the subsequent 7 days; in orthopedic surgery: 100 U / kg (41 IU / kg) for 12 hour before and 12 hours after surgery, next day during 3 days, then - 150 U / kg (61 IU / kg) 10 days. If necessary, the introduction is continued until the full recovery of motor activity of the patient.

Precautions.

It is necessary before treatment, and then (long-term therapy) 2 twice a week to carry out counting the number of blood platelets. The drug should be discontinued with the appearance of skin necrosis at the injection site. The risk of bleeding is higher in renal insufficiency and in women over the age of 60 years.

Cooperation